Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Greco, Ines ^a   Day, Nicola ^b   Riddoch Contreras, Joanna ^a   Reed, Jane ^b   Soininen, Hilkka ^c   Kłoszewska, Iwona ^d   Tsolaki, Magda ^e   Vellas, Bruno ^f   Spenger, Christian ^g   Mecocci, Patrizia ^h   Wahlund, Lars Olof ^g   Simmons, Andrew ^a   Barnes, Julie ^b,i   Lovestone, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BioWisdom Ltd   (United Kingdom)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ ABCODIA LTD   (United Kingdom)

Author keywords

Alzheimer's disease; Bioinformatics; Biomarkers; Choline acetyltransferase (ChAt); in silico; Intelligence network; Literature mining; MRI; Proteomics; Urokinase type plasminogen activator receptor (PLAUR)

Indexed keywords

BIOLOGICAL MARKER; CHOLINE ACETYLTRANSFERASE; UROKINASE RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; COMPUTER MODEL; DATA BASE; DATA MINING; IMAGE ANALYSIS; IMMUNODETECTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; VALIDITY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; INFORMATION STORAGE AND RETRIEVAL;

EID: 84868250727     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-217     Document Type: Article

References (30)

1. Lovestone S, Guntert A, Hye A, Lynham S, Thambisetty M, Ward M. Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. Expert Rev Proteomics 2007, 4(2):227-238. 10.1586/14789450.4.2.227, 17425458.
2. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 2011, 95(4):579-593. 10.1016/j.pneurobio.2010.11.005, 21130138.
3. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6(3):131-144. 10.1038/nrneurol.2010.4, 20157306.
4. Verwey NA, Van Der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. AnnClinBiochem 2009, 46(Pt 3):235-240.
5. Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. BiomarkMed 2010, 4(1):65-79.
6. Thambisetty M, Tripaldi R, Riddoch-Contreras J, Hye A, An Y, Campbell J, Sojkova J, Kinsey A, Lynham S, Zhou Y, et al. Proteome-based plasma markers of brain amyloid-beta deposition in non-demented older individuals. J Alzheimers Dis 2010, 22(4):1099-1109. 3125970, 20930274.
7. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. ArchGenPsychiatry 2010, 67(7):739-748.
8. Klein J, Jupp S, Moulos P, Fernandez M, Buffin-Meyer B, Casemayou A, Chaaya R, Charonis A, Bascands JL, Stevens R, et al. The KUPKB: a novel Web application to access multiomics data on kidney disease. FASEB J 2012, 26(5):2145-2153. 10.1096/fj.11-194381, 22345404.
9. Reorganizing the protein space at the Universal Protein Resource (UniProt) Nucleic Acids Res 2012, 40(Database issue):D71-75. 3245120, 22102590, Reorganizing the protein space at the Universal Protein Resource (UniProt).
10. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol 2010, 23(1):171-183. 10.1021/tx900326k, 2850112, 20014752.
11. Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, Soininen H, Spenger C, Tsolaki M, Vellas B, Wahlund LO, et al. AddNeuroMed-the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. AnnNYAcadSci 2009, 1180:36-46.
12. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, et al. The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 2011, 26(1):75-82. 10.1002/gps.2491, 21157852.
13. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, et al. MRI measures of Alzheimer's disease and the AddNeuroMed study. AnnNYAcadSci 2009, 1180:47-55.
14. Westman E, Simmons A, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Weiner MW, Lovestone S, et al. AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 2011, 58(3):818-828. 10.1016/j.neuroimage.2011.06.065, 21763442.
15. Westman E, Simmons A, Zhang Y, Muehlboeck JS, Tunnard C, Liu Y, Collins L, Evans A, Mecocci P, Vellas B, et al. Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage 2011, 54(2):1178-1187. 10.1016/j.neuroimage.2010.08.044, 20800095.
16. Velayudhan L, Killick R, Hye A, Kinsey A, Guentert A, Lynham S, Ward M, Leung R, Lourdusamy A, To AW, et al. Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis 2012, 28(2):369-375.
17. Mancinella A, Mancinella M, Carpinteri G, Bellomo A, Fossati C, Gianturco V, Iori A, Ettorre E, Troisi G, Marigliano V. Is there a relationship between high C-reactive protein (CRP) levels and dementia?. Arch Gerontol Geriatr 2009, 49(Suppl 1):185-194.
18. Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement 2009, 5(4):318-323. 10.1016/j.jalz.2009.04.1230, 2740472, 19560102.
19. Davis G, Baboolal N, Nayak S, McRae A. Sialic acid, homocysteine and CRP: potential markers for dementia. Neurosci Lett 2009, 465(3):282-284. 10.1016/j.neulet.2009.09.035, 19766699.
20. Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, et al. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry 2011, 68(2):207-213. 10.1001/archgenpsychiatry.2010.196, 21300948.
21. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41(10):1094-1099. 10.1038/ng.439, 19734903.
22. Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. NeurolSci 2002, 23(Suppl 2):S95-S96.
23. Ewers M, Zhong Z, Burger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008, 131(Pt 5):1252-1258.
24. Kassner SS, Bonaterra GA, Kaiser E, Hildebrandt W, Metz J, Schroder J, Kinscherf R. Novel systemic markers for patients with Alzheimer disease? - a pilot study. Curr Alzheimer Res 2008, 5(4):358-366. 10.2174/156720508785132253, 18690833.
25. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010, 584(9):1923-1930. 10.1016/j.febslet.2009.12.039, 20036661.
26. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010, 11(1):23-36. 10.1038/nrm2821, 20027185.
27. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3(12):932-943. 10.1038/nrm977, 12461559.
28. Davis J, Wagner MR, Zhang W, Xu F, Van Nostrand WE. Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem 2003, 278(21):19054-19061. 10.1074/jbc.M301398200, 12754271.
29. Walker DG, Lue LF, Beach TG. Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains. Brain Res 2002, 926(1-2):69-79.
30. Asahina M, Yoshiyama Y, Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 2001, 20(2):60-63.